AI-generated summary. We recommend consulting the bill text for important decisions.

Expanding on existing Utah law, this bill requires that suppliers of biological materials used in stem cell therapy — such as placental or other tissue-based products — first obtain written confirmation from the health care provider that the provider will properly notify patients before performing any FDA-unapproved stem cell therapy. That patient notice must be displayed prominently in the provider's office, included in any advertisements, and accompanied by a signed consent form explaining the treatment's approval status, anticipated results, possible risks, and alternatives.